Case report
Efficacy of Rituximab in Dermatomyositis and Polymyositis Refractory to Conventional Therapy
Eficacia de rituximab en dermatomiositis y polimiositis refractarias al tratamiento convencional
Simón Ángel Sánchez-Fernández
, José Antonio Carrasco Fernández, Luisa Marena Rojas Vargas
Corresponding author
Sección de Reumatología, Hospital La Mancha Centro, Alcázar de San Juan, Spain
Read
15889
Timeswas read the article
3243
Total PDF
12646
Total HTML
| Year/Month | Html | Total | |
|---|---|---|---|
| 2025 6 | 16 | 48 | 64 |
| 2025 5 | 343 | 44 | 387 |
| 2025 4 | 257 | 26 | 283 |
| 2025 3 | 253 | 38 | 291 |
| 2025 2 | 242 | 48 | 290 |
| 2025 1 | 241 | 43 | 284 |
| 2024 12 | 183 | 43 | 226 |
| 2024 11 | 194 | 75 | 269 |
| 2024 10 | 142 | 49 | 191 |
| 2024 9 | 169 | 17 | 186 |
| 2024 8 | 154 | 26 | 180 |
| 2024 7 | 220 | 40 | 260 |
| 2024 6 | 156 | 31 | 187 |
| 2024 5 | 135 | 42 | 177 |
| 2024 4 | 137 | 24 | 161 |
| 2024 3 | 151 | 31 | 182 |
| 2024 2 | 103 | 29 | 132 |
| 2024 1 | 121 | 27 | 148 |
| 2023 12 | 95 | 36 | 131 |
| 2023 11 | 115 | 30 | 145 |
| 2023 10 | 126 | 43 | 169 |
| 2023 9 | 141 | 49 | 190 |
| 2023 8 | 122 | 24 | 146 |
| 2023 7 | 88 | 28 | 116 |
| 2023 6 | 88 | 19 | 107 |
| 2023 5 | 42 | 16 | 58 |
| 2023 4 | 58 | 4 | 62 |
| 2023 3 | 140 | 28 | 168 |
| 2023 2 | 104 | 34 | 138 |
| 2023 1 | 109 | 26 | 135 |
| 2022 12 | 154 | 35 | 189 |
| 2022 11 | 134 | 38 | 172 |
| 2022 10 | 134 | 45 | 179 |
| 2022 9 | 121 | 44 | 165 |
| 2022 8 | 109 | 44 | 153 |
| 2022 7 | 101 | 42 | 143 |
| 2022 6 | 128 | 41 | 169 |
| 2022 5 | 109 | 59 | 168 |
| 2022 4 | 130 | 52 | 182 |
| 2022 3 | 162 | 56 | 218 |
| 2022 2 | 142 | 38 | 180 |
| 2022 1 | 159 | 41 | 200 |
| 2021 12 | 107 | 57 | 164 |
| 2021 11 | 131 | 46 | 177 |
| 2021 10 | 119 | 76 | 195 |
| 2021 9 | 93 | 51 | 144 |
| 2021 8 | 90 | 56 | 146 |
| 2021 7 | 79 | 46 | 125 |
| 2021 6 | 139 | 60 | 199 |
| 2021 5 | 152 | 33 | 185 |
| 2021 4 | 271 | 77 | 348 |
| 2021 3 | 184 | 58 | 242 |
| 2021 2 | 103 | 24 | 127 |
| 2021 1 | 110 | 30 | 140 |
| 2020 12 | 90 | 29 | 119 |
| 2020 11 | 86 | 25 | 111 |
| 2020 10 | 57 | 11 | 68 |
| 2020 9 | 60 | 18 | 78 |
| 2020 8 | 60 | 27 | 87 |
| 2020 7 | 55 | 19 | 74 |
| 2020 6 | 40 | 24 | 64 |
| 2020 5 | 59 | 15 | 74 |
| 2020 4 | 51 | 17 | 68 |
| 2020 3 | 21 | 10 | 31 |
| 2020 2 | 2 | 0 | 2 |
| 2019 7 | 0 | 2 | 2 |
| 2019 5 | 1 | 0 | 1 |
| 2019 1 | 1 | 0 | 1 |
| 2018 5 | 6 | 4 | 10 |
| 2018 4 | 77 | 10 | 87 |
| 2018 3 | 108 | 10 | 118 |
| 2018 2 | 49 | 6 | 55 |
| 2018 1 | 49 | 6 | 55 |
| 2017 12 | 72 | 5 | 77 |
| 2017 11 | 75 | 7 | 82 |
| 2017 10 | 76 | 12 | 88 |
| 2017 9 | 88 | 17 | 105 |
| 2017 8 | 117 | 20 | 137 |
| 2017 7 | 111 | 7 | 118 |
| 2017 6 | 106 | 19 | 125 |
| 2017 5 | 125 | 23 | 148 |
| 2017 4 | 94 | 14 | 108 |
| 2017 3 | 92 | 53 | 145 |
| 2017 2 | 78 | 16 | 94 |
| 2017 1 | 83 | 13 | 96 |
| 2016 12 | 122 | 17 | 139 |
| 2016 11 | 131 | 17 | 148 |
| 2016 10 | 158 | 27 | 185 |
| 2016 9 | 249 | 19 | 268 |
| 2016 8 | 146 | 9 | 155 |
| 2016 7 | 94 | 21 | 115 |
| 2016 5 | 0 | 8 | 8 |
| 2016 2 | 1 | 0 | 1 |
| 2016 1 | 3 | 25 | 28 |
| 2015 12 | 2 | 0 | 2 |
| 2015 11 | 1 | 0 | 1 |
| 2015 10 | 3 | 12 | 15 |
| 2015 9 | 1 | 0 | 1 |
| 2015 8 | 1 | 0 | 1 |
| 2015 7 | 53 | 7 | 60 |
| 2015 6 | 79 | 12 | 91 |
| 2015 5 | 144 | 13 | 157 |
| 2015 4 | 114 | 14 | 128 |
| 2015 3 | 87 | 12 | 99 |
| 2015 2 | 102 | 8 | 110 |
| 2015 1 | 85 | 9 | 94 |
| 2014 12 | 78 | 18 | 96 |
| 2014 11 | 80 | 9 | 89 |
| 2014 10 | 67 | 12 | 79 |
| 2014 9 | 66 | 16 | 82 |
| 2014 8 | 74 | 10 | 84 |
| 2014 7 | 62 | 17 | 79 |
| 2014 6 | 117 | 22 | 139 |
| 2014 5 | 95 | 20 | 115 |
| 2014 4 | 82 | 14 | 96 |
| 2014 3 | 91 | 19 | 110 |
| 2014 2 | 64 | 27 | 91 |
| 2014 1 | 73 | 20 | 93 |
| 2013 12 | 66 | 19 | 85 |
| 2013 11 | 59 | 13 | 72 |
| 2013 10 | 74 | 17 | 91 |
| 2013 9 | 59 | 21 | 80 |
| 2013 8 | 69 | 30 | 99 |
| 2013 7 | 53 | 19 | 72 |
| 2013 6 | 49 | 27 | 76 |
| 2013 5 | 64 | 39 | 103 |
| 2013 4 | 33 | 18 | 51 |
Show all
